Durable efficacy of alemtuzumab in CARE-MS II patients with highly active relapsing-remitting multiple sclerosis: 4-year outcomes

Affiliation auteursAffiliation ok
TitreDurable efficacy of alemtuzumab in CARE-MS II patients with highly active relapsing-remitting multiple sclerosis: 4-year outcomes
Type de publicationJournal Article
Year of Publication2015
AuteursKrieger S., Freedman M.S, Moreau T., Havrdova E., Selmaj K.W, Margolin D.H, Kasten L., Investigators CARE-MSII
JournalMULTIPLE SCLEROSIS JOURNAL
Volume21
Pagination573
Date PublishedSEP
Type of ArticleMeeting Abstract
ISSN1352-4585